Gowthami M. Arepally

Gowthami M. Arepally

Hematology

40 Duke Medicine Cir
Durham, NC 27710

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Methods to Examine Complement Activation by HIT Immune Complexes.

Methods to Examine Complement Activation by HIT Immune Complexes.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: September 02, 2026

False-negative immunoassays in heparin induced thrombocytopenia.

False-negative immunoassays in heparin induced thrombocytopenia.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 09, 2026

The influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.

The influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: January 12, 2026

Red cell exchange removes apixaban in patients with sickle cell disease.

Red cell exchange removes apixaban in patients with sickle cell disease.

Journal: Transfusion

Published: December 08, 2025

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Journal: Blood

Published: November 14, 2025

Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner.

Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 19, 2025

Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.

Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2025

Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.

Targeting PIEZO1-TMEM16F Coupling to Mitigate Sickle Cell Disease Complications.

Journal: American journal of hematology

Published: June 04, 2025

Escherichia coli Type III Secretion System 2 Is Associated With Patient Mortality in Bloodstream Infections.

Escherichia coli Type III Secretion System 2 Is Associated With Patient Mortality in Bloodstream Infections.

Journal: The Journal of infectious diseases

Published: December 01, 2024

Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.

Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 23, 2024

Red cell exchange modulates neutrophil degranulation responses in sickle cell disease.

Red cell exchange modulates neutrophil degranulation responses in sickle cell disease.

Journal: Transfusion

Published: April 30, 2024

Showing 1-12 of 82

Last Updated: 09/26/2026